Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Christopher L. Lynch is active.

Publication


Featured researches published by Christopher L. Lynch.


Bioorganic & Medicinal Chemistry Letters | 2002

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 4: Synthesis of N-1 acidic functionality affording analogues with enhanced antiviral activity against HIV

Christopher L. Lynch; Jeffrey J. Hale; Richard J. Budhu; Amy Gentry; Sander G. Mills; Kevin T. Chapman; Malcolm Maccoss; Lorraine Malkowitz; Martin S. Springer; Sandra L. Gould; Julie A. DeMartino; Salvatore J. Siciliano; Margaret A. Cascieri; Anthony Carella; Gwen Carver; Karen Holmes; William A. Schleif; Renee Danzeisen; Daria J. Hazuda; Joseph Kessler; Janet Lineberger; Michael D. Miller; Emilio A. Emini

A series of alpha-(pyrrolidin-1-yl)acetic acids is presented as selective and potent antivirals against HIV. Several of the pyrrolidine zwitterions demonstrated reasonable in vitro properties, enhanced antiviral activities and improved pharmacokinetic profiles over pyrrolidine 1.


Bioorganic & Medicinal Chemistry Letters | 2002

CCR5 antagonists: bicyclic isoxazolidines as conformationally constrained N-1-substituted pyrrolidines

Christopher L. Lynch; Amy Gentry; Jeffrey J. Hale; Sander G. Mills; Malcolm Maccoss; Lorraine Malkowitz; Martin S. Springer; Sandra L. Gould; Julie A. DeMartino; Salvatore J. Siciliano; Margaret A. Cascieri; George A. Doss; Anthony Carella; Gwen Carver; Karen Holmes; William A. Schleif; Renee Danzeisen; Daria J. Hazuda; Joseph Kessler; Janet Lineberger; Michael D. Miller; Emilio A. Emini

A series of CCR5 antagonists containing bicyclic isoxazolidines was generated through a nitrone mediated cycloaddition with olefins bearing the preferred pharmacophores previously described. Potent antagonists (3 and 16) were generated with enhanced affinity for the CCR5 receptor while maintaining antiviral activity against HIV.


Bioorganic & Medicinal Chemistry Letters | 2003

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists: modifications of the arylpropylpiperidine side chains.

Christopher L. Lynch; Christopher A. Willoughby; Jeffrey J. Hale; Edward J. Holson; Richard J. Budhu; Amy Gentry; Keith G. Rosauer; Charles G. Caldwell; Ping Chen; Sander G. Mills; Malcolm Maccoss; Scott C. Berk; Liya Chen; Kevin T. Chapman; Lorraine Malkowitz; Martin S. Springer; Sandra L. Gould; Julie A. DeMartino; Salvatore J. Siciliano; Margaret A. Cascieri; Anthony Carella; Gwen Carver; Karen Holmes; William A. Schleif; Renee Danzeisen; Daria J. Hazuda; Joseph Kessler; Janet Lineberger; Michael D. Miller; Emilio A. Emini

The 4-(3-phenylprop-1-yl)piperidine moiety of the 1,3,4-trisubstituted pyrrolidine CCR5 antagonist 1 was modified with electron deficient aromatics as well as replacement of the benzylic methylene with sulfones, gem-difluoromethylenes and alcohols in an effort to balance the antiviral potency with reasonable pharmacokinetics.


Science | 2002

Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists

Suzanne M. Mandala; Richard Hajdu; James D. Bergstrom; Elizabeth J. Quackenbush; Jenny Xie; James A. Milligan; Rosemary A. Thornton; Gan-Ju Shei; Deborah Card; CarolAnn Keohane; Mark Rosenbach; Jeffrey J. Hale; Christopher L. Lynch; Kathleen M. Rupprecht; William H. Parsons; Hugh Rosen


Archive | 2000

Pyrrolidine modulators of ccr5 chemokine receptor activity

Jeffrey J. Hale; Christopher L. Lynch; Charles G. Caldwell; Christopher A. Willoughby; Dooseop Kim; Dong-Ming Shen; Sander G. Mills; Kevin T. Chapman; Liya Chen; Amy Gentry; Malcolm Maccoss; Zenon Konteatis


Archive | 1998

Pyrrolidine and piperidine modulators of chemokine receptor activity

Richard J. Budhu; Edward Holson; Jeffrey J. Hale; Christopher L. Lynch; Malcolm Maccoss; Scott C. Berk; Sander G. Mills; Christopher A. Willoughby


Archive | 2003

Edg receptor agonists

Robert L. Bugianesi; George Doherty; Amy Gentry; Jeffrey J. Hale; Christopher L. Lynch; Sander G. Mills; William E. Neway


Bioorganic & Medicinal Chemistry Letters | 2005

Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties.

Dooseop Kim; Liping Wang; Jeffrey J. Hale; Christopher L. Lynch; Richard J. Budhu; Malcolm Maccoss; Sander G. Mills; Lorraine Malkowitz; Sandra L. Gould; Julie A. DeMartino; Martin S. Springer; Daria J. Hazuda; Michael D. Miller; Joseph Kessler; Renee Hrin; Gwen Carver; Anthony Carella; Karen Henry; Janet Lineberger; William A. Schleif; Emilio A. Emini


Journal of Medicinal Chemistry | 2005

Discovery of Potent 3,5-Diphenyl-1,2,4-oxadiazole Sphingosine-1-phosphate-1 (S1P1) Receptor Agonists with Exceptional Selectivity against S1P2 and S1P3

Zhen Li; Weirong Chen; Jeffrey J. Hale; Christopher L. Lynch; Sander G. Mills; Richard Hajdu; Carol Ann Keohane; Mark Rosenbach; James A. Milligan; Gan-Ju Shei; Gary Chrebet; Stephen A. Parent; James D. Bergstrom; Deborah Card; Michael J. Forrest; Elizabeth J. Quackenbush; L. Alexandra Wickham; Hugo M. Vargas; Rose M. Evans; and Hugh Rosen; Suzanne M. Mandala


Archive | 2003

1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists

Weirong Chen; Jeffrey J. Hale; Zhen Li; Christopher L. Lynch; Sander G. Mills; William E. Neway

Collaboration


Dive into the Christopher L. Lynch's collaboration.

Researchain Logo
Decentralizing Knowledge